1. Academic Validation
  2. Characterisation of neuroprotective efficacy of modified poly-arginine-9 (R9) peptides using a neuronal glutamic acid excitotoxicity model

Characterisation of neuroprotective efficacy of modified poly-arginine-9 (R9) peptides using a neuronal glutamic acid excitotoxicity model

  • Mol Cell Biochem. 2017 Feb;426(1-2):75-85. doi: 10.1007/s11010-016-2882-z.
Adam B Edwards 1 2 3 Ryan S Anderton 4 5 Neville W Knuckey 4 6 7 Bruno P Meloni 4 6 7
Affiliations

Affiliations

  • 1 Western Australian Neuroscience Research Institute, A Block, 4th Floor, QEII Medical Centre, Verdun St, Nedlands, WA, 6009, Australia. adam.edwards1@my.nd.edu.au.
  • 2 School of Health Sciences, The University of Notre Dame Australia, Fremantle, WA, 6160, Australia. adam.edwards1@my.nd.edu.au.
  • 3 Department of Neurosurgery, Sir Charles Gardiner Hospital, QEII Medical Centre, Nedlands, WA, 6009, Australia. adam.edwards1@my.nd.edu.au.
  • 4 Western Australian Neuroscience Research Institute, A Block, 4th Floor, QEII Medical Centre, Verdun St, Nedlands, WA, 6009, Australia.
  • 5 School of Health Sciences, The University of Notre Dame Australia, Fremantle, WA, 6160, Australia.
  • 6 Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, WA, 6009, Australia.
  • 7 Department of Neurosurgery, Sir Charles Gardiner Hospital, QEII Medical Centre, Nedlands, WA, 6009, Australia.
Abstract

In a recent study, we highlighted the importance of cationic charge and arginine residues for the neuroprotective properties of poly-arginine and arginine-rich Peptides. In this study, using cortical neuronal cultures and an in vitro glutamic acid excitotoxicity model, we examined the neuroprotective efficacy of different modifications to the poly-arginine-9 peptide (R9). We compared an unmodified R9 peptide with R9 Peptides containing the following modifications: (i) C-terminal amidation (R9-NH2); (ii) N-terminal acetylation (Ac-R9); (iii) C-terminal amidation with N-terminal acetylation (Ac-R9-NH2); and (iv) C-terminal amidation with D-amino acids (R9D-NH2). The three C-terminal amidated Peptides (R9-NH2, Ac-R9-NH2, and R9D-NH2) displayed neuroprotective effects greater than the unmodified R9 peptide, while the N-terminal acetylated peptide (Ac-R9) had reduced efficacy. Using the R9-NH2 peptide, neuroprotection could be induced with a 10 min peptide pre-treatment, 1-6 h before glutamic acid insult, or when added to neuronal cultures up to 45 min post-insult. In addition, all Peptides were capable of reducing glutamic acid-mediated neuronal intracellular calcium influx, in a manner that reflected their neuroprotective efficacy. This study further highlights the neuroprotective properties of poly-arginine Peptides and provides insight into peptide modifications that affect efficacy.

Keywords

Arginine-rich peptides; Cell-penetrating peptides; Cortical neurons; Glutamate excitotoxicity; Neuroprotection; Poly-arginine peptides.

Figures
Products